Brief: Knight Signs New Exclusive Ambisome Agreement With Gilead In Brazil
26/10/2020 11:31
Oct 26 (Reuters) - Knight Therapeutics Inc GUD.TO :
* KNIGHT SIGNS NEW EXCLUSIVE AMBISOME® AGREEMENT WITH GILEAD
IN
BRAZIL
* KNIGHT THERAPEUTICS INC - AGREEMENT WILL BE EFFECTIVE
STARTING
JANUARY 1, 2021
Source text for Eikon: ID:nGNX4Yr9xN
Further company coverage: GUD.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil